Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY2 | P41231 | 12/20 | 0.56 |
| ▸ | P2RY4 | P51582 | 4/20 | 0.56 |
| ▸ | P2RY6 | Q15077 | 4/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | POLA1 | P09884 | 1/20 | 0.51 |
| ▸ | POLD1 | P28340 | 1/20 | 0.51 |
| ▸ | P2RY14 | Q15391 | 4/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17859264 | 1.00 | P2RY2 (0.56) | P2RY2P2RY4P2RY6POLBPOLA1 | |
| SCHEMBL21577339 | 0.92 | P2RY2 (0.55) | P2RY2P2RY4P2RY6P2RY14 | |
| SCHEMBL17859261 | 0.92 | P2RY2 (0.55) | P2RY2P2RY4P2RY6P2RY14 | |
| SCHEMBL15810738 | 0.92 | P2RY2 (0.65) | P2RY2P2RY4P2RY6P2RY14 | |
| SCHEMBL17211000 | 0.92 | P2RY2 (0.65) | P2RY2P2RY4P2RY6P2RY14 | |
| SCHEMBL21577305 | 0.92 | P2RY2 (0.65) | P2RY2P2RY4P2RY6P2RY14 | |
| SCHEMBL22095729 | 0.92 | P2RY2 (0.65) | P2RY2P2RY4P2RY6P2RY14 | |
| SCHEMBL19329266 | 0.92 | P2RY2 (0.65) | P2RY2P2RY4P2RY6P2RY14 | |
| SCHEMBL17859271 | 0.92 | P2RY2 (0.65) | P2RY2P2RY4P2RY6P2RY14 | |
| SCHEMBL18852485 | 0.92 | P2RY2 (0.65) | P2RY2P2RY4P2RY6P2RY14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11364257-B2 | Phosphoramidates for the treatment of hepatitis B virus | EMORY UNIVERSITY (US) | 2022-06-21 | — | — | US | disclosed |
| US-20210395290-A1 | PHOSPHORAMIDATES FOR THE TREATMENT OF HEPATITIS B VIRUS | EMORY UNIVERSITY | 2021-12-23 | — | — | US | disclosed |
| US-10683319-B2 | Phosphoramidates for the treatment of hepatitis B virus | EMORY UNIVERSITY (US) | 2020-06-16 | — | — | US | disclosed |
| US-20190350954-A1 | PHOSPHORAMIDATES FOR THE TREATMENT OF HEPATITIS B VIRUS | EMORY UNIVERSITY | 2019-11-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190350954-A1 | PHOSPHORAMIDATES FOR THE TREATMENT OF HEPATITIS B VIRUS | TYMP, PNP, HPRT1 | P2RY2 1228/4885P2RY4 280/4885P2RY6 390/4885 |
| US-11364257-B2 | Phosphoramidates for the treatment of hepatitis B virus | TYMP, PNP, HPRT1 | P2RY2 1228/4885P2RY4 280/4885P2RY6 390/4885 |
| US-10683319-B2 | Phosphoramidates for the treatment of hepatitis B virus | TYMP, PNP, MTAP | P2RY2 1863/4885P2RY4 616/4885P2RY6 805/4885 |
| US-20210395290-A1 | PHOSPHORAMIDATES FOR THE TREATMENT OF HEPATITIS B VIRUS | TYMP, PNP, MTAP | P2RY2 1863/4885P2RY4 616/4885P2RY6 805/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.